Book a Meeting

Non-fucosylated Anti-Human CGRP (Fremanezumab) Therapeutic Antibody (CAT#: BioBet-093ZP) Datasheet

Target
CGRP
Isotype
IgG2, κ
Description
ADCC-enhanced Fremanezumab is a non-fucosylated anti-CGRP therapeutic biobetter antibody.
Indication
Migraine
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CGRP antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CALCA and CALCB
Alternative Names
CALCA; calcitonin related polypeptide alpha; CT; KC; PCT; CGRP; CALC1; CGRP1; CGRP-I
Gene ID
796
UniProt ID
P01258
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with CALCA include Reflex Sympathetic Dystrophy and Spinal Stenosis.
Related Pathways
Its related pathways are Neuroscience and Signaling by GPCR.
Function
How CGRP induces vasodilation. It dilates a variety of blood vessels, including coronary arteries, brain and blood vessels throughout the body. Its abundance in the central nervous system also indicates that it has the effect of neurotransmitter or neurotonin. It also increases platelet cAMP.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Neuroscience antibody; Signaling Transduction antibody
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2, κ
Antibody Clone
Fremanezumab
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CGRP. Fremanezumab is a humanized monoclonal antibody that can be potentially used in the treatment of Migraine. It binds to and inhibits the activity of CGRP.
Indication
Migraine

Migraine

Related Products

BetterBet™ Anti-CGRP Half-Life Extended Antibody (CAT#: AES-0622-ZP1096)
BetterBet™ Anti-CGRP Recycling Antibody (CAT#: AES-0622-ZP112)
Non-Fucosylated Anti-Human CGRP (ALD403) Therapeutic Antibody (CAT#: BioBet-706ZP)
Highly Galactosylated Anti-CGRP (Fremanezumab) Antibody (CAT#: BioBet-GA-093ZP)
Highly Galactosylated Anti-CGRP (Eptinezumab) Antibody (CAT#: BioBet-GA-092ZP)
Non-fucosylated Anti-Human CGRP (Galcanezumab) Therapeutic Antibody (CAT#: BioBet-094ZP)
Highly Galactosylated Anti-CGRP (Galcanezumab) Antibody (CAT#: BioBet-GA-094ZP)
BetterBet™ Anti-CGRP FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP440)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany